BRD2 and ovarian hyperstimulation syndrome: Physicians may therefore be more likely to adjust the FSH dose in those patients receiving a GnRH agonist compared with a GnRH antagonist, in order to reduce the OHSS risk, which is supported by the findings of this systematic review.